Medtronic plc (NYSE:MDT) Conference Call Summary Company Overview - **Company**: Medtronic plc - **Event**: Goldman Sachs Global Healthcare Conference Call - **Date**: June 14, 2022 - **Participants**: Geoff Martha (Chairman & CEO), Amit Hazan (Goldman Sachs Medical Technology Analyst) Key Points Industry Context - The healthcare industry, particularly medical technology, has faced significant challenges due to COVID-19 and supply chain disruptions [4][5][6] - Medtronic has played a critical role in responding to the pandemic, particularly with ventilators [4] Supply Chain Challenges - Medtronic experienced acute supply chain issues, particularly with semi chips and resins affecting their Energy business and packaging [7][8] - A supplier explosion caused significant disruptions in the Surgical Innovations business [8] - Supply chain issues are expected to improve, particularly in the second half of the fiscal year [9] - The company is implementing structural changes to enhance supply chain resiliency, moving from a fragmented approach to a centralized model [11][12][14] Financial Guidance and Revenue Expectations - Medtronic is guiding for 4% to 5% revenue growth for the fiscal year, despite challenges in the previous quarters [22][24] - The company anticipates easier comparisons in the second half of the fiscal year due to lower bases from the previous year [25] - Key product launches are expected to drive growth, including new TAVR and EV ICD products [26] Research and Development (R&D) - Medtronic aims to increase R&D spending to outpace sales growth, focusing on higher-growth opportunities [28] - The company is committed to improving R&D productivity and has streamlined operations to allow for increased investment [29] Operating Margins - Medtronic is targeting a return to pre-COVID operating margins of around 28% [30][32] - The company is focused on achieving 5% top-line growth and 8% EPS growth, alongside a growing dividend [32][33] Product Development and Market Position - The surgical robot is expected to see significant growth, with positive feedback from international markets [34][36] - Medtronic is optimistic about the diabetes segment, with the 780G system showing promising results in trials [41][43] - The company is also focused on the renal denervation (RDN) market, with ongoing trials expected to yield positive results [48][49] Market Dynamics in China - Short-term challenges include navigating COVID lockdowns and pricing pressures, but long-term growth in China is still anticipated [53][54] - Medtronic acknowledges increased risks in the Chinese market due to geopolitical factors but remains bullish on investment opportunities [55] Capital Allocation and Portfolio Management - Medtronic is conducting a deep dive into its portfolio to ensure capital is allocated to higher-growth areas [57] - Ongoing evaluations may lead to divestitures or restructuring within the portfolio [57] Additional Insights - The company is adapting to a new normal in supply chain management, balancing efficiency with resiliency [11][14] - Medtronic's strategy includes leveraging acquisitions and partnerships to enhance R&D capabilities [29] - The focus on integrated insulin delivery systems positions Medtronic favorably in the diabetes market [44][46] This summary encapsulates the key insights and strategic directions discussed during the conference call, highlighting Medtronic's response to current challenges and its plans for future growth.

Medtronic plc (NYSE:MDT) Q4 2022 Earnings Conference Call May 26, 2022 8:00 AM ET Company Participants Ryan Weispfenning - Head of IR Geoff Martha - CEO Karen Parkhill - CFO Brad Lerman - SVP, General Counsel, Corporate Secretary Bob White - EVP and President of the Medical Surgical Portfolio Sean Salmon - EVP and President of the Cardiovascular Portfolio Conference Call Participants Vijay Kumar - Evercore ISI Travis Steed - Bank of America Merrill Lynch Larry Biegelsen - Wells Fargo Shagun Singh - RBC Ca ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 28, 2022 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from __________ to __________ Commission File Number 001-36820 ® Medtronic plc (Exact name of registrant as specified in its charter) Ireland 98-1183488 (State of incorporation) (I.R ...